ISU Abxis Co., Ltd. (KOSDAQ:086890)

South Korea flag South Korea · Delayed Price · Currency is KRW
4,975.00
+145.00 (3.00%)
At close: Apr 23, 2026
Market Cap201.81B +13.4%
Revenue (ttm)56.67B -6.0%
Net Income-10.68B
EPSn/a
Shares Out40.77M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume586,641
Average Volume122,719
Open4,900.00
Previous Close4,830.00
Day's Range4,835.00 - 5,030.00
52-Week Range4,410.00 - 6,350.00
Beta0.67
RSI54.83
Earnings Daten/a

About ISU Abxis

ISU Abxis Co., Ltd., a biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide. The company offers Abcertin, an imiglucerase for injection that is used as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Type 1 Gaucher disease; Fabagal, an agalsidase beta for injection, which is used as a long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease; Clotinab, an abciximab that is used as an adjunct to percutaneous coronary inte... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2001
Employees 178
Stock Exchange KOSDAQ
Ticker Symbol 086890
Full Company Profile

Financial Performance

Financial Statements